REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN US PATIENTS NEWLY DIAGNOSED WITH GLIOBLASTOMA MULTIFORME (GBM) BY O6-METHYLGUANINE DNA METHYLTRANSFERASE PROMOTOR (MGMT) STATUS
Author(s)
Fu A1, Gogate A1, Hall J2, Bailey A2, Massey L2, Marshall A1
1Bristol-Myers Squibb, Lawrenceville, NJ, USA, 2Adelphi Real World, Bollington, UK
Presentation Documents
OBJECTIVES MGMT-methylation is a biomarker predictive of improved treatment potential and favourable survival in GBM patients. This study explored the relationship between MGMT testing, treatment patterns, and outcomes of newly diagnosed US GBM patients. MATERIALS AND METHODS : US based medical/neuro-oncologists completed a cross-sectional survey providing clinical and demographic information for GBM patients between March and October 2019 (GBM Disease-specific ProgrammeTM). Statistically significant differences (p<0.05) between groups are presented. RESULTS 40 physicians reported on 326 1L GBM patients, predominantly male (65%) and middle-aged (mean 60.3, SD 14.6 years). 174 (53%) received MGMT testing, of whom 91 (52%) were methylated and 83 (48%) unmethylated. Overall, 59% of patients received surgery, 77% temozolomide, 64% radiotherapy, and 10% tumor-treating fields. MGMT-tested patients (vs. MGMT-untested patients) had a better ECOG score (0-1: 72% vs 51%), were more likely to be located in Northeast US (48% vs 22%), respond to treatment (33% vs 27%), have a tumor resectable at diagnosis (68% vs 44%), receive surgery (73% vs 42%), receive radiotherapy (86% vs 40%) with fewer courses (1.3 vs 1.8), but less likely to finish their course (40% vs 22%); more likely to receive temozolomide (95% vs 56%) and less likely to receive bevacizumab (5% vs 20%). MGMT-methylated patients (vs. MGMT-unmethylated patients) were more likely to have a tumor resectable at diagnosis (76% vs 59%), longer time since diagnosis (19.5 vs 13.2 weeks), better physician-perceived prognosis (77.4 vs 61.1 weeks) and receive systemic treatment for longer (12.9 vs 8.8 weeks). CONCLUSIONS Nearly half of newly diagnosed US GBM patients were not MGMT tested. Tested patients had better treatment response than untested patients. MGMT-methylated patients had better prognosis, were more likely to be resectable at diagnosis and received systemic treatment for longer. An unmet treatment need remains for patients that have not been MGMT-tested or are MGMT-unmethylated.
Conference/Value in Health Info
2020-05, ISPOR 2020, Orlando, FL, USA
Value in Health, Volume 23, Issue 5, S1 (May 2020)
Code
PCN347
Topic
Clinical Outcomes
Topic Subcategory
Clinician Reported Outcomes
Disease
Drugs, Oncology, Surgery